Press Releases Acurx Pharmaceuticals, Inc.

Stocks

ACXP

US00510M2035

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 23:01:30 11/06/2026 HKT			5-day change	1st Jan Change
1.560 ^USD	-2.50%		-11.86%	-37.35%

05-20	Acurx Pharmaceuticals Highlights FDA's Guidance That Could Accelerate Approval Path for Ibezapolstat	CI
05-12	Acurx Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 12, 2026

Press Releases

05-20	Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat	AQ
05-12	Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update	PR
05-04	Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026	PR
04-30	Acurx Pharmaceuticals : ESCMID Poster Presentation “Preclinical Microbiome Evaluation of novel PolC-inhibitor compounds (Begum, et. al., April 2026)"	PU
04-29	Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase	PR
04-27	Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit	NE
04-20	Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update	PR
04-17	Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	PR
04-16	Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	PR
04-08	New to The Street Resigns Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) to Continue Long-Form Interview Series, Outdoor Media Campaigns and Accredited Investor Events	AQ
04-04	New to The Street Announces Episode 741 Airing Tonight on Bloomberg Television at 6:30 PM EST Featuring Canton Networks, Acme Markets, Virtuix Holdings (VTIX), HPB, Jonas & Redman, Acurx Pharmaceuticals (ACXP), and FreeCast (CAST)	AQ
03-30	Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors	PR
03-13	Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update	PR
03-09	Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection	PR
02-16	Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update	PR
02-02	USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors	PR
11-18	Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals	PR
11-12	Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update	PR
11-10	Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens	PR
28/10/25	Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference	PR
27/10/25	Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update	PR
09/10/25	Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors	PR
30/09/25	Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection	PR
03/09/25	Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules	PR
28/08/25	Acurx Pharmaceuticals : Corporate Presentation dated September 2025	PU